Latest ulcerative colitis research from ECCO 2016

Researchers presented data and clinical updates on diabetes at the European Crohn’s and Colitis Organization’s Congress.

Coverage featured news from the conference and research implications on patient care and practice.

FMT induces remission in resistant ulcerative colitis

Intense multidonor fecal microbiota transplantation administered via colonoscopy and enema effectively induced clinical and endoscopic remission in patients with resistant active ulcerative colitis, according to the results of a randomized, placebo-controlled trial. Read more.

TOUCHSTONE: Patients with UC achieve histological improvements with ozanimod

Patients with moderate-to-severe ulcerative colitis achieved histologic improvement and histologic remission with 1 mg ozanimod, according to results from the TOUCHSTONE phase 2 clinical trial. Read more.

GEMINI: UC patients achieve long-term clinical improvement with Entyvio

Patients with moderate-to-severely active ulcerative colitis reported clinical improvements with up to 3 years of treatment with Entyvio, according to interim data from the GEMINI Long-Term Safety trial. Read more.

Xeljanz induces remission in patients with ulcerative colitis; modest results in Crohn’s trials

Xeljanz rapidly induced remission in patients with moderate-to-severe ulcerative colitis, according to results from the OCTAVE 1 and 2 trials. Read more.

GO-COLITIS: Simponi induces clinical response in patients with ulcerative colitis

Simponi induced clinical response in more than two-thirds of patients with moderate-to-severe ulcerative colitis in the induction phase of the GO-COLITIS trial. Read more.